Search Bar & Filters
Found 356 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are investigating new treatment options for extensive-stage small cell lung cancer ES-SCLC, a type of lung cancer that has spread widely within the lungs or to other parts of the body. This study evaluates the combination of two investigational drugs, gocatamig and ifinatamab deruxtecan I-DXd, alongside standard chemotherapy and immunotherapy treatments. The research aims to understand the safety and tolerability of these combined therapies and whether they can reduce or eliminate cancer in participants. Participants in the trial may receive different treatment regimens depending on their prior therapy history. Some will receive gocatamig and I-DXd together in maintenance after standard chemotherapy and immunotherapy, while others will receive these drugs during both induction and maintenance phases. Additional groups will receive combinations including gocatamig, I-DXd, atezolizumab, carboplatin, and etoposide in varying sequences. Treatments are delivered intravenously, and participants continue until disease progression or other criteria require stopping. During the study, participants will have regular assessments including imaging to measure tumor response, safety monitoring for adverse events, and laboratory tests to understand drug levels and immune reactions. Researchers will track side effects, dose-limiting toxicities, and treatment discontinuations over a period of up to about 58 months. The main outcomes include tumor response and safety, with ongoing evaluation of disease control, survival, and drug exposure throughout the study duration.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.
Actively Recruiting
Researchers are evaluating MK-1045, an immunotherapy, for treating two types of non-Hodgkin lymphoma NHL follicular lymphoma FL, which grows slowly, and diffuse large B-cell lymphoma DLBCL, which grows quickly. NHL is a cancer of the lymphatic system causing swollen lymph nodes. The study aims to learn about the safety and tolerability of MK-1045 and whether it helps reduce or eliminate these lymphomas. Participants are randomly assigned to one of four groups receiving MK-1045 in different doses and methods intravenous IV infusion or subcutaneous SC injection. Treatment continues for up to approximately one year or until participants stop. The study includes phases 1b and 2 and involves optimizing doses and schedules, including longer dosing intervals and subcutaneous administration. During the study, participants will have regular assessments including monitoring for adverse events, response to treatment using the Lugano Response Criteria, and measuring drug levels in the body. Researchers will track safety up to about 49 months and monitor discontinuation due to side effects for up to 12 months. Tumor tissue samples and other laboratory tests will also be collected to understand treatment effects. The total participation can last several years with ongoing evaluations.
Actively Recruiting
Researchers are investigating new treatment options for people with certain advanced or metastatic solid tumors that have alterations in the KRAS gene. This Phase 1 trial aims to evaluate the safety and tolerability of the drug MK-4716 when taken alone or in combination with other treatments. The study focuses on understanding possible side effects and how well participants tolerate these therapies. Participants will receive MK-4716 either by itself at different dose levels and schedules, or in combination with Pembrolizumab or Cetuximab, both given by intravenous infusion. The study has multiple groups running in parallel, each receiving one of these treatment approaches. MK-4716 is taken orally, and the combinations involve intravenous administration of the other drugs. During the trial, participants will be closely monitored for any dose-limiting toxicities and adverse events up to approximately 4 years. Researchers will assess drug levels in the blood at set timepoints to understand how MK-4716 behaves in the body. Participants will undergo regular evaluations including safety checks and measuring disease status. The study duration may extend over several years to gather long-term safety and response information.
Actively Recruiting
Researchers are studying MK-8294, a targeted therapy designed to treat advanced or metastatic solid tumors such as head and neck squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, triple-negative breast cancer, certain hormone receptor-positive breast cancers, endometrial, and bladder cancers. This Phase 1, open-label study aims to evaluate the safety, tolerance, and highest dose of MK-8294 that patients can handle. The study is sponsored by Merck Sharp & Dohme LLC and focuses on treatment for participants who have failed standard therapies or have no other options. Participants will receive MK-8294 alone through intravenous infusion at escalating doses starting from 30 micrograms up to 70 milligrams, including possible intermediate doses. The drug is administered on Days 1, 8, and 15 of each 21-day cycle, with no maximum number of cycles specified. Treatment continues until discontinuation criteria are met. Optional imaging with a CD8 PET tracer may be performed as part of the study. During the study, participants will be closely monitored for adverse events and treatment tolerance up to two years. Evaluations include blood tests measuring MK-8294 drug levels and immune responses, as well as safety assessments for dose-limiting toxicities. The study tracks objective tumor responses along with the presence of antidrug antibodies. Participants will have regular visits for treatment and assessments throughout their participation, which may last several cycles depending on individual response and tolerability.
Actively Recruiting
Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.
Actively Recruiting
Researchers are evaluating treatments for high-grade serous and certain other types of ovarian cancer that tend to grow and spread quickly. This study focuses on advanced cancers that started in the ovaries, lining of the belly, or fallopian tubes. The trial aims to assess the safety, tolerability, and response of a study drug called Raludotatug Deruxtecan R-DXd, which is an antibody drug conjugate designed to target and destroy cancer cells. This research includes a dose escalation phase followed by an expansion phase using the recommended dose. Participants will receive R-DXd through intravenous infusions every three weeks, often combined with other anticancer treatments such as carboplatin, paclitaxel, bevacizumab, pembrolizumab, or MK-2010. These combinations vary across different groups in the study, with some receiving up to six cycles of chemotherapy drugs over approximately four months, and others receiving immunotherapy or targeted therapy for longer periods, up to two years. The study allows continued treatment with R-DXd until disease progression or discontinuation. During the trial, participants will undergo regular clinical assessments including imaging scans to measure tumor response, monitoring for side effects, and laboratory tests. The main outcomes include tracking dose-limiting toxicities, adverse events, treatment discontinuations due to side effects, objective tumor response, and progression-free survival. Follow-up may continue for up to several years to evaluate longer-term effects and survival. The total duration of participation depends on treatment response and tolerability.
1-10 of 356
1